The potential role of iNKT cells in experimental allergic encephalitis and multiple sclerosis

References

• Hagemeier K, Brück W, Kuhlmann T. Multiple sclerosis-remyelination failure as a cause of disease progression. Histol Histopathol 2012;27:277–287
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Investig 2001;81:263–281
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 2006;354:942–955
   PubMed Web of Science ®Google Scholar
• Mirshafiey A. Novel promising therapeutic agents in multiple sclerosis. Recent Patents Inflamm Allergy Drug Discov 2007;1:218–224
   PubMedGoogle Scholar
• Bjartmar C, Wujek J, Trapp B. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165–171
   PubMed Web of Science ®Google Scholar
• Bø L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323–331
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705–2712
   PubMed Web of Science ®Google Scholar
• Pulizzi A, Rovaris M, Judica E, et al. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol 2007;64:1163–1168
   PubMed Web of Science ®Google Scholar
• Bailey-Bucktrout SL, Caulkins SC, Goings G, et al. Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J Immunol 2008;180:6457–6461
   PubMed Web of Science ®Google Scholar
• Nicot AB. Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci 2009;14:4477–4515
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Matsuo H, Nakane S, et al. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol 2005;27:255–265
   PubMed Web of Science ®Google Scholar
• Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE ε4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:203–205
   PubMed Web of Science ®Google Scholar
• Haines J, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nat Genet 1996;13:469–471
   PubMed Web of Science ®Google Scholar
• Myhr KM, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999;52:1771–1776
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Dyment D, Ebers GC. Genetic epidemiology of multiple sclerosis. Epidemiol Rev 1997;19:99–106
   PubMed Web of Science ®Google Scholar
• Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–219
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Konstantinidou AD. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosc 2007;12:1615–1628
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Kempuraj D, Iliopoulou BP. Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Immune Mediated Dis 2007;601:423–430
   Google Scholar
• Stefferl A, Brehm U, Storch M, et al. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the “resistant” Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 1999;163:40–49
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345–350
   PubMed Web of Science ®Google Scholar
• Thakker P, Leach MW, Kuang W, et al. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007;178:2589–2598
   PubMed Web of Science ®Google Scholar
• Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002;25:313–319
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009;31:13–29
   PubMed Web of Science ®Google Scholar
• Hutter C. On the causes of multiple sclerosis. Med Hypotheses 1993;41:93–96
   PubMed Web of Science ®Google Scholar
• Berlanga-Taylor AJ, Ramagopalan SV. Vitamin D and multiple sclerosis: what is the clinical impact? Exp Opin Med Diagn 2013;7:227–229
   PubMedGoogle Scholar
• Furlan R, Kurne A, Bergami A, et al. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol 2004;150:10–19
   PubMed Web of Science ®Google Scholar
• Murphy ÁC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010;24:641–651
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006;176:7768–7774
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, et al. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol 2008;195:140–145
   PubMed Web of Science ®Google Scholar
• Hur EM, Youssef S, Haws ME, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2006;8:74–83
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008;181:7480–7488
   PubMed Web of Science ®Google Scholar
• Benveniste EN. Cytokines: influence on glial cell gene expression and function. Chem Immunol 1997;69:31–75
   PubMedGoogle Scholar
• Yamamura T, Sakuishi K, Illés Z, Miyake S. Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 2007;191:8–15
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001;413:531–534
   PubMed Web of Science ®Google Scholar
• Pál E, Tabira T, Kawano T, et al. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells. J Immunol 2001;166:662–668
   PubMed Web of Science ®Google Scholar
• Simoni Y, Diana J, Ghazarian L, et al. Therapeutic manipulation of NKT cells in autoimmunity: are we close to reality? Clin Exp Immunol 2013;171:8–19
   PubMed Web of Science ®Google Scholar
• Cohen NR, Brennan PJ, Shay T, et al. Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells. Nat Immunol 2012;14:90–99
   PubMed Web of Science ®Google Scholar
• Mussai F, De Santo C, Cerundolo V. Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities. J Immunother 2012;35:449–459
   Google Scholar
• Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005;3:e113
   PubMed Web of Science ®Google Scholar
• Balato A, Unutmaz D, Gaspari AA. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J Investig Dermatol 2009;129:1628–1642
   PubMed Web of Science ®Google Scholar
• Mercer JC, Ragin MJ, August A. Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 2005;37:1337–1343
   PubMed Web of Science ®Google Scholar
• Chuang YP, Wang CH, Wang NC, et al. Modulatory function of invariant natural killer T cells in systemic lupus erythematosus. Clin Dev Immunol 2012;2012:478429
   PubMedGoogle Scholar
• Emoto M, Emoto Y. Intracellular bacterial infection and invariant NKT cells. Yonsei Med J 2009;50:12–21
   PubMed Web of Science ®Google Scholar
• Cohen NR, Garg S, Brenner MB. Antigen presentation by CD1: lipids, T cells, and NKT cells in microbial immunity. Adv Immunol 2009;102:1–94
   PubMed Web of Science ®Google Scholar
• Liu Y, Teige A, Mondoc E, et al. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Investig 2011;121:249–264
   PubMed Web of Science ®Google Scholar
• Barral P, Polzella P, Bruckbauer A, et al. CD169+ macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010;11:303–312
   PubMed Web of Science ®Google Scholar
• Lawson V. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells. Immunology 2012;137:20–27
   PubMed Web of Science ®Google Scholar
• Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. Curr Opin Immunol 2008;20:358–368
   PubMed Web of Science ®Google Scholar
• Wu L, Gabriel C, Parekh V, Van Kaer L. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 2009;73:535–545
   PubMed Web of Science ®Google Scholar
• Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol 2013;34:50–58
   PubMed Web of Science ®Google Scholar
• Brigl M, Tatituri RVV, Watts GFM, et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 2011;208:1163–1177
   Google Scholar
• Parekh VV, Wilson MT, Van Kaer L. iNKT-cell responses to glycolipids. Crit Rev Immunol 2005;25:183–214
   PubMed Web of Science ®Google Scholar
• Gapin L. iNKT cell autoreactivity: what is ‘self’ and how is it recognized? Nat Rev Immunol 2010;10:272–277
   PubMed Web of Science ®Google Scholar
• Yu ED, Girardi E, Wang J, Zajonc DM. Cutting edge: structural basis for the recognition of β-linked glycolipid antigens by invariant NKT cells. J Immunol 2011;187:2079–2083
   PubMed Web of Science ®Google Scholar
• Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000;192:741–754
   PubMed Web of Science ®Google Scholar
• MacDonald HR. Development and selection of NKT cells. Curr Opin immunol 2002;14:250–254
   PubMed Web of Science ®Google Scholar
• Shimamura M, Ohteki T, Beutner U, Robson MacDonald H. Lack of directed Vα14-Jα281 rearrangements in NK1+ T cells. Eur J Immunol 2005;27:1576–1579
   Google Scholar
• Das R, Sant’Angelo DB, Nichols KE. Transcriptional control of invariant NKT cell development. Immunol Rev 2010;238:195–215
   Google Scholar
• Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 2007;7:505–518
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013;13:101–117
   PubMed Web of Science ®Google Scholar
• Seiler MP, Mathew R, Liszewski MK, et al. Elevated and sustained expression of the transcription factors Egr1 and Egr2 controls NKT lineage differentiation in response to TCR signaling. Nat Immunol 2012;13:264–271
   PubMed Web of Science ®Google Scholar
• Mathew R, Seiler MP, Scanlon ST, et al. BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs. Nature 2012;491:618–621
   PubMed Web of Science ®Google Scholar
• Becker AM, Blevins JS, Tomson FL, et al. Invariant NKT cell development requires a full complement of functional CD3 ζ immunoreceptor tyrosine-based activation motifs. J Immunol 2010;184:6822–6832
   PubMed Web of Science ®Google Scholar
• Griewank K, Borowski C, Rietdijk S, et al. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 2007;27:751–762
   PubMed Web of Science ®Google Scholar
• Eberl G, Lowin-Kropf B, MacDonald HR. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice. J Immunol 1999;163:4091–4094
   PubMed Web of Science ®Google Scholar
• Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999;190:1189–1196
   PubMed Web of Science ®Google Scholar
• Nichols KE, Hom J, Gong SY, et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005;11:340–345
   PubMed Web of Science ®Google Scholar
• Pasquier B, Yin L, Fondanèche MC, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005;201:695–701
   PubMed Web of Science ®Google Scholar
• Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999;189:1121–1128
   PubMed Web of Science ®Google Scholar
• Brigl M, Bry L, Kent SC, et al. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003;4:1230–1237
   PubMed Web of Science ®Google Scholar
• Watarai H, Sekine-Kondo E, Shigeura T, et al. Development and function of invariant natural killer T cells producing TH2-and TH17-cytokines. PLoS Biol 2012;10:e1001255
   Web of Science ®Google Scholar
• Kim HY, Pichavant M, Matangkasombut P, et al. The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells. J Immunol 2009;182:3252–3261
   PubMed Web of Science ®Google Scholar
• Michel M-L, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1. 1neg iNKT cell population involved in airway neutrophilia. J Exp Med 2007;204:995–1001
   PubMed Web of Science ®Google Scholar
• Coquet JM, Chakravarti S, Kyparissoudis K, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4− NK1. 1− NKT cell population. Proc Natl Acad Sci USA 2008;105:11287–11292
   PubMed Web of Science ®Google Scholar
• Hansen DS, Schofield L. Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells. Int J Parasitol 2004;34:15–25
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis EES, Matsumoto T, Exley M, et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002;8:588–593
   PubMed Web of Science ®Google Scholar
• Kinjo Y, Tupin E, Wu D, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006;7:978–986
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Tashiro T, Dashtsoodol N, et al. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 2010;22:1–6
   Google Scholar
• Toura I, Kawano T, Akutsu Y, et al. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999;163:2387–2391
   PubMed Web of Science ®Google Scholar
• van der Vliet HJJ, Molling JW, von Blomberg BME, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004;112:8–23
   PubMed Web of Science ®Google Scholar
• Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003;3:211–222
   PubMed Web of Science ®Google Scholar
• Jahng AW, Maricic I, Pedersen B, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1789–1799
   PubMed Web of Science ®Google Scholar
• Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001;7:1057–1062
   PubMed Web of Science ®Google Scholar
• Seino K, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci 2001;98:2577–2581
   PubMed Web of Science ®Google Scholar
• Ikehara Y, Yasunami Y, Kodama S, et al. CD4+ Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Investig 2000;105:1761–1768
   PubMed Web of Science ®Google Scholar
• Sonoda KH, Faunce DE, Taniguchi M, et al. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001;166:42–50
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Investig 2004;114:1379–1403
   PubMed Web of Science ®Google Scholar
• Lee PT, Putnam A, Benlagha K, et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Investig 2002;110:793–800
   PubMed Web of Science ®Google Scholar
• Hammond K, Godfrey D. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens 2002;59:353–363
   PubMedGoogle Scholar
• Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Investig 2002;109:131–140
   PubMed Web of Science ®Google Scholar
• Kojo S, Adachi Y, Keino H, et al. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001;44:1127–1138
   PubMed Web of Science ®Google Scholar
• Novak J, Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011;53:263–270
   PubMed Web of Science ®Google Scholar
• Singh N, Hong S, Scherer DC, et al. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999;163:2373–2377
   PubMed Web of Science ®Google Scholar
• Burdin N, Brossay L, Kronenberg M. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999;29:2014–2025
   PubMed Web of Science ®Google Scholar
• Yang J-Q, Singh AK, Wilson MT, et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003;171:2142–2153
   PubMed Web of Science ®Google Scholar
• Novak J, Beaudoin L, Griseri T, Lehuen A. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J Immunol 2005;174:1954–1961
   PubMed Web of Science ®Google Scholar
• Cain JA, Smith JA, Ondr JK, et al. NKT cells and IFN-γ establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J Immunol 2006;176:1645–1654
   PubMed Web of Science ®Google Scholar
• Walker KM, Rytelewski M, Mazzuca DM, et al. Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist. Immunol Cell Biol 2011;90:630–639
   PubMed Web of Science ®Google Scholar
• Chiba A, Kaieda S, Oki S, et al. The involvement of Vα14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum 2005;52:1941–1948
   PubMedGoogle Scholar
• Yang J-Q, Wen X, Kim PJ, Singh RR. Invariant NKT cells inhibit autoreactive B cells in a contact-and CD1d-dependent manner. J Immunol 2011;186:1512–1520
   PubMed Web of Science ®Google Scholar
• Araki M, Kondo T, Gumperz JE, et al. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003;15:279–288
   PubMed Web of Science ®Google Scholar
• Takahashi T, Nakamura K, Chiba S, et al. Vα24+ natural killer T cells are markedly decreased in atopic dermatitis patients. Hum Immunol 2003;64:586–592
   PubMed Web of Science ®Google Scholar
• Novak J, Beaudoin L, Park S, et al. Prevention of type 1 diabetes by invariant NKT cells is independent of peripheral CD1d expression. J Immunol 2007;178:1332–1340
   PubMed Web of Science ®Google Scholar
• Croxford JL, Miyake S, Huang Y-Y, et al. Invariant Vα19i T cells regulate autoimmune inflammation. Nat Immunol 2006;7:987–994
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Zhao J, Yang L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc Nutr Soc 2012;1:1–5
   Google Scholar
• Mars LT, Laloux V, Goude K, et al. Cutting edge: Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002;168:6007–6011
   PubMed Web of Science ®Google Scholar
• Wiethe C, Schiemann M, Busch D, et al. Interdependency of MHC class II/self-peptide and CD1d/self-glycolipid presentation by TNF-matured dendritic cells for protection from autoimmunity. J Immunol 2007;178:4908–4916
   PubMed Web of Science ®Google Scholar
• Mars LT, Gautron A-S, Novak J, et al. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 2008;181:2321–2329
   PubMed Web of Science ®Google Scholar
• Parekh VV, Singh AK, Wilson MT, et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J Immunol 2004;173:3693–3706
   PubMed Web of Science ®Google Scholar
• Karl O, Im JS, Molano A, et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci USA 2005;102:3383–3388
   PubMed Web of Science ®Google Scholar
• O’Keeffe J, Gately CM, Counihan T, et al. T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to α-galactosylceramide are impaired. J Neurol Sci 2008;275:22–28
   PubMed Web of Science ®Google Scholar
• Monteiro M, Almeida CF, Caridade M, et al. Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-β. J Immunol 2010;185:2157–2163
   PubMed Web of Science ®Google Scholar
• Behi ME, Dubucquoi S, Lefranc D, et al. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Lett 2005;96:11–26
   PubMed Web of Science ®Google Scholar
• Horikoshi M, Goto D, Segawa S, et al. Activation of invariant NKT cells with glycolipid ligand α-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis. PLoS One 2012;7:e51215
   PubMed Web of Science ®Google Scholar
• Yamamura T. Therapeutic strategy for multiple sclerosis targeting NK and NKT cells. Clin Neurol 2001;41:1162–1164
   Google Scholar
• Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J Immunol 2002;168:2028–2034
   PubMed Web of Science ®Google Scholar
• Oh SJ, Chung DH. Invariant NKT cells producing IL-4 or IL-10, but not IFN-γ, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response. J Immunol 2011;186:6815–6821
   PubMed Web of Science ®Google Scholar
• Mars LT, Araujo L, Kerschen P, et al. Invariant NKT cells inhibit development of the Th17 lineage. Proc Natl Acad Sci USA 2009;106:6238–6343
   PubMed Web of Science ®Google Scholar
• Qian G, Qin X, Zang YQ, et al. High doses of α-galactosylceramide potentiate experimental autoimmune encephalomyelitis by directly enhancing Th17 response. Cell Res 2010;20:480–491
   PubMed Web of Science ®Google Scholar
• Jahng A, Maricic I, Aguilera C, et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004;199:947–957
   PubMed Web of Science ®Google Scholar
• Parekh VV, Wu L, Olivares-Villagómez D, et al. Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J Immunol 2013;190:1948–1960
   Google Scholar
• Denney L, Kok WL, Cole SL, et al. Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome. J Immunol 2012;189:551–557
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Miyake S, Yamamura T. Role of NK cells and invariant NKT cells in multiple sclerosis. Molecular Basis of Multiple Sclerosis: Springer; 2010:127–147
   Google Scholar
• Yamamura T. Involvement of NK and NKT cells in the pathogenesis of multiple sclerosis. Nihon Rinsho Jpn J Clin Med 2003;61:1329–1334
   PubMedGoogle Scholar
• Kent SC, Chen Y, Clemmings SM, et al. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 2005;175:4458–4464
   PubMed Web of Science ®Google Scholar
• Démoulins T, Gachelin G, Bequet D, Dormont D. A biased Vα24+ T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. Immunol Lett 2003;90:223–228
   PubMed Web of Science ®Google Scholar
• Illés Z, Kondo T, Newcombe J, et al. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000;164:4375–4381
   PubMed Web of Science ®Google Scholar
• Miyake S, Yamamura T. NKT cells and autoimmune diseases: unraveling the complexity. T cell activation by CD1 and lipid antigens. 2007;314:251–267
   Google Scholar
• Moreira-Teixeira L, Resende M, Devergne O, et al. Rapamycin combined with TGF-β converts human invariant NKT Cells into suppressive Foxp3+ regulatory cells. J Immunol 2012;188:624–631
   PubMed Web of Science ®Google Scholar